http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CR-20190012-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a693232b92910547c898db10feb83fef
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2017-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_891fd611c0f60e0a83676dabb0f1e578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34d02c5e54b5f557a610b910b3cab433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc16ce54d2fe8d53e7ac58b63c9e4853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f7b5b59f366fd7a00b2977e64fcddcf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3036c6c9a055278032bc41b67570921a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81ae5484e83b3c68cfcd34a3f9ed72a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4170199f9a53daffb9070d218d9bd545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa1fdbf82b567682f08b84cf76d8930a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9431cfb26a2944524e48400205c6f00d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74d14a6b537547ad1323cd43902d7be5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ff85d84145fdf6fe482c3d093b9728d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6903774c87e7769d1fcad1014b104148
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d7e51844cc2410bb570deb42d6b327f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6340702a0a68c68fdd0f3414d105bb5
publicationDate 2019-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CR-20190012-A
titleOfInvention SPECIFIC ANTIBODIES FOR HYPERPHOSPHORILED TAUY AND ITS METHODS OF USE
abstract The present invention relates to a class of monoclonal antibody that specifically binds to phosphorylated serine residue 396 in hyperphosphorylated pathological tau (PHF) (pS396) with improved affinity, as well as methods of using these molecules and its tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
priorityDate 2016-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396493

Total number of triples: 27.